Novus progressus, MB - financials and debts

Company age: 2 y. 8 mo.

Update

Novus progressus - Company finances

EUR
2024
From: 2024-01-23
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 4,615 10,535
Profit before tax -485 594
Net profit -485 583
Equity -85 498
Liabilities 3,054 2,826
Non-current assets 2,429 1,959
Current assets 540 1,365
Total assets 2,969 3,324
Taxes paid
STI taxes 390 623
Financial indicators
Revenue change y/y - +128.3%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. -16.3% 17.5%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. - 117.1%
Profit margin Net profit margin. Shows the overall profitability of the company. -10.5% 5.5%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. -10.5% 5.6%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. - 5.7
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Novus progressus - Social security debts

The amount of overdue SODRA debt for the company Novus progressus as of the last working day is: 161 €

From To Debt, €
2026-09-05 2026-09-14 160.96
2026-09-01 2026-09-02 160.96
2026-08-26 2026-08-31 80.48
2026-08-23 2026-08-23 80.48
2026-08-19 2026-08-19 80.48
2026-08-16 2026-08-17 80.48
2026-08-01 2026-08-14 80.48
2026-07-01 2026-07-31 241.44
2026-06-02 2026-06-30 160.96
2026-05-03 2026-06-01 80.48
2026-04-01 2026-04-30 241.44
2026-03-03 2026-03-31 160.96
2026-02-03 2026-03-02 80.48
2024-03-01 2024-04-30 64.50

Novus progressus - VMI tax arrears

As of 2026-09-02, the amount of overdue STI tax debt of the company Novus progressus is: 55 €

From To Overdue, €
2026-09-01 2026-09-02 55.23
2026-08-31 2026-08-31 54.92
2026-08-14 2026-08-30 54.76
2026-08-06 2026-08-13 0.05
2026-08-02 2026-08-05 49.78
2026-07-09 2026-08-01 49.31
2026-07-02 2026-07-08 0.76
2026-06-30 2026-07-01 72.75
2026-06-18 2026-06-29 72.29
2026-04-30 2026-06-17 0.4
2026-04-17 2026-04-29 0.32
2026-03-20 2026-03-27 49.19
2026-03-18 2026-03-18 48.86
2026-03-11 2026-03-17 0.33
2026-03-02 2026-03-10 112.6
2026-02-21 2026-03-01 112.33
2026-02-13 2026-02-20 0.27
2026-01-22 2026-02-03 0.04
2026-01-20 2026-01-21 97.89
2026-01-16 2026-01-19 97.35
2025-12-17 2026-01-15 0.29
2025-10-26 2025-12-16 0.07
2025-10-18 2025-10-22 48.55
2025-09-19 2025-10-17 0.02
2025-09-05 2025-09-18 0.04
2025-09-01 2025-09-04 48.73
2025-08-28 2025-08-31 48.6
2025-08-01 2025-08-27 0.07
2025-07-18 2025-07-22 48.68
2025-07-16 2025-07-17 0.15
2025-07-02 2025-07-15 0.14
2025-07-01 2025-07-01 48.74
2025-06-19 2025-06-30 48.6
2025-05-28 2025-06-18 0.07
2025-05-17 2025-05-20 48.91
2025-05-07 2025-05-16 48.61
2025-03-26 2025-05-06 0.08
2025-03-20 2025-03-25 48.54
2025-02-26 2025-03-19 0.01
2025-02-25 2025-02-25 48.6
2025-02-22 2025-02-24 48.53
2025-02-20 2025-02-20 75.0
2025-02-02 2025-02-02 48.69
2025-01-18 2025-02-01 48.53
2024-12-19 2024-12-19 97.67
2024-11-01 2024-12-18 0.61
2024-10-12 2024-10-31 48.93
2024-08-21 2024-10-11 0.4

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Novus progressus, MB (code 306667295) is a Lithuanian small partnership operating in other human health activities n.e.c. In the latest financial year, 2025, the company generated revenue of €10.5K, which was 128.3% higher than in 2024, when revenue was €4.6K. Profitability also improved: net profit reached €583 in 2025 after a net loss of €485 in 2024, and the profit margin moved to 5.5% from -10.5%. The balance sheet remained small but strengthened slightly during the year. Total assets stood at €3.3K, equity at €498 and liabilities at €2.8K. Long-term assets amounted to €2.0K, while short-term assets were €1.4K. Key ratios show a high return on equity of 117.1% and return on assets of 17.5%, both influenced by the limited equity base. Debt to equity was 5.67 and the equity ratio was 15.0%, indicating that liabilities still exceed own funds. Asset turnover reached 3.17x in 2025, reflecting stronger use of the asset base alongside revenue growth.